# Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

> **NCT04023552** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 8323 (actual)

## Conditions studied

- Cardiovascular Disease and Lipoprotein(a)

## Interventions

- **DRUG:** TQJ230
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04023552
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-12
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 8323 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04023552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04023552, "Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04023552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*